Olaparib with abiraterone and prednisone or prednisolone is recommended, within its marketing authorisation, as an option for untreated hormone-relapsed metastatic prostate cancer in adults who cannot have or do not want chemotherapy. It is only recommended if the company provides it according to the commercial arrangements.
Why the committee made these recommendations
Usual treatment for untreated hormone-relapsed metastatic prostate cancer is abiraterone or enzalutamide.
Clinical trial evidence shows that olaparib with abiraterone and prednisone or prednisolone increases how long people live and how long they have before their cancer gets worse compared with abiraterone alone. Olaparib with abiraterone and prednisone or prednisolone has not been directly compared with enzalutamide.
The cost-effectiveness estimates are within the range that NICE considers an acceptable use of NHS resources. So, olaparib with abiraterone and prednisone or prednisolone is recommended.